Results 21 to 30 of about 2,816 (233)

Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer? [PDF]

Investigative and Clinical Urology, 2021
Purpose: Lutetium labelled prostate-specific membrane antigen radioligand therapy (Lu-PSMA RLT) has shown pleasing early results in management of high-volume metastatic castration resistant prostate cancer (mCRPC), but its role in the early treatment of ...
William John Yaxley, Rhiannon McBean, David Wong, David Grimes, Paul Vasey, Mark Frydenberg, John William Yaxley   +6 more
doaj   +1 more source

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors [PDF]

, 2017
Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options.
Al‐nahhas, A, Ansquer, C, Anthony, L, Azevedo, I, Baudin, E, Baum, Rp, Baum, Rp, Benson, A, Benson, Ab, Berlin, J, Berlin, J, Bodei, L, Brianzoni, E, Bushnell, D, Bushnell, D, Caplin, M, Caplin, M, Chasen, B, Chiara Grana, M, Courbon, F, DELLE FAVE, Gianfranco, Delpassand, E, Delpassand, E, El Haddad, G, Erion, Jl, Freemantle, N, Garbus, S, Giammarile, F, Grande, E, Grande, E, Grossman, A, Hendifar, A, Hendifar, A, Hobday, T, Hobday, T, Jacene, H, Krenning, E, Kulkarni, Hr, Kulke, M, Kulke, Mh, Kunz, Pl, Kvols, L, Kwekkeboom, D, Lebtahi, R, Lopera Sierra, M, Manoharan, P, Mariani, G, Metz, D, Mittra, E, Mittra, E, Mora, J, Mora, J, Morse, M, O'Dorisio, Tm, Pavel, M, Pavel, M, Reed, N, Reed, N, Rindi, G, Ruszniewski, P, Ruszniewski, P, Santoro, P, Scheidhauer, K, Schipper, M, Seregni, E, Seregni, E, Severi, S, Srirajaskanthan, R, Srirajaskanthan, R, Strosberg, J, Strosberg, J, Sundin, A, Taieb, D, Thevenet, T, Van Cutsem, E, Van Cutsem, E, Weber, M, Wolin, E, Wolin, E, Yao, J, Yao, J., Öberg, K, Öberg, K   +82 more
core   +1 more source

In vitro characterisation of [177Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer

EJNMMI Radiopharmacy and Chemistry, 2023
Background Pancreatic ductal adenocarcinoma (PDAC) continues to be a malignancy with an unmet clinical demand. Development of radioimmunoconjugates which target cancer-specific receptors provides an opportunity for radioimmunotherapy of both metastatic ...
Ashleigh Hull, William Hsieh, William Tieu, Dylan Bartholomeusz, Yanrui Li, Eva Bezak   +5 more
doaj   +1 more source

Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma

Cells, 2022
Mucin 1 is a transmembrane glycoprotein which overexpresses cancer-specific epitopes (MUC1-CE) on pancreatic ductal adenocarcinoma (PDAC) cells. As PDAC is a low survival and highly aggressive malignancy, developing radioimmunoconjugates capable of ...
Ashleigh Hull, Yanrui Li, Dylan Bartholomeusz, William Hsieh, William Tieu, Tara L. Pukala, Alexander H. Staudacher, Eva Bezak   +7 more
doaj   +1 more source

Lu-177-labeled zirconia particles for radiation synovectomy [PDF]

, 2015
The present article describes the preparation of beta emitter lutetium-177-lebeled zirconia colloid and its preliminary physico-chemical and biological evaluation of suitability for local radionuclide therapy.
Balogh, Lajos, Bóta, Attila, Dabasi, Gabriella, Drotár, Eszter, Jóba, Róbert Péter, Mikolajczak, Renata, Naszályi Nagy, Lívia, Polyák, András, Pöstényi, Zita   +8 more
core   +1 more source

Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent [PDF]

, 2016
Prostate-specific membrane antigen (PSMA) is a well-established target for nuclear imaging and therapy of prostate cancer (PCa). Radiolabeled small-molecule PSMA inhibitors are excellent candidates for PCa theranostics-they rapidly and efficiently ...
Boerman, O.C. (Otto), Chatalic, K.L.S. (Kristell), Clahsen-van Groningen, M.C. (Marian), Franssen, G.M. (Gerben), Heskamp, S. (Sandra), Jong, M. (Marcel) de, Konijnenberg, M. (Mark), Molkenboer-Kuenen, J.D.M. (Janneke D.M.), Schottelius, M. (Margret), Weerden, W.M. (Wytske) van, Wester, H.-J. (Hans-Jürgen)   +10 more
core   +1 more source

An assessment tumor targeting ability of 177Lu labeled cyclic CCK analogue peptide by binding with cholecystokinin receptor

Journal of Pharmacological Sciences, 2016
The cholecystokinin (CCK) receptor is known as a receptor that is overexpressed in many human tumors. The present study was designed to investigate the targeting ability of cyclic CCK analogue in AR42J pancreatic cells. The CCK analogues, DOTA-K(glucose)-
Eun-Ha Cho, Jae Cheong Lim, So-Young Lee, Sung-Hee Jung   +3 more
doaj   +1 more source

The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).

BMC Cancer, 2023
Background Isolated local failure (ILF) can occur in patients who initially receive definitive radiation therapy for prostate cancer. Salvage therapy for ILF includes high dose rate (HDR) brachytherapy.
Lucas C. Mendez, Aneesh Dhar, David Laidley, Madeleine Moussa, Jose A. Gomez, Joseph Chin, T-Y Lee, Jonathan D. Thiessen, Douglas Hoover, Kathleen Surrey, Joelle Helou, Vikram Velker, Rohann J. Correa, David D’Souza, Jane Bayani, Glenn Bauman   +15 more
doaj   +1 more source

Mechanical suppression of osteolytic bone metastases in advanced breast cancer patients: A randomised controlled study protocol evaluating safety, feasibility and preliminary efficacy of exercise as a targeted medicine [PDF]

, 2018
Background: Skeletal metastases present a major challenge for clinicians, representing an advanced and typically incurable stage of cancer. Bone is also the most common location for metastatic breast carcinoma, with skeletal lesions identified in over 80%
Chee, Raphael, Clay, Tim, Feeney, Kynan T, Galvao, Daniel A, Hart, Nicolas H, Martin, Hilary, Newton, Robert U, Redfern, Andrew D, Saunders, Christobel, Spry, Nigel A, Taaffe, Dennis R, Tsoi, Daphne   +11 more
core   +7 more sources

Validation of $$^{99m}$$ 99 m Tc and $$^{177}$$ 177 Lu quantification parameters for a Monte Carlo modelled gamma camera

EJNMMI Physics, 2023
Purpose Monte Carlo (MC) simulation in Nuclear Medicine is a powerful tool for modeling many physical phenomena which are difficult to track or measure directly. MC simulation in SPECT/CT imaging is particularly suitable for optimizing the quantification
Giovanni Di Domenico, Simona Di Biaso, Lorenzo Longo, Alessandro Turra, Eugenia Tonini, MariaConcetta Longo, Licia Uccelli, Mirco Bartolomei   +7 more
doaj   +1 more source